Phase 1B/II Study of Escalating Doses of Pevonedistat (TAK-924, Formerly MLN4924) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pevonedistat (Primary) ; Cytarabine; Idarubicin
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

12 Dec 2023 Results(n=28) presented at the 65th American Society of Hematology Annual Meeting and Exposition, investigating the safety and efficacy of pevonedistat in combination with 7+3 cytarabine and idarubicin induction chemotherapy in adults with high-risk AML.
15 Feb 2023 Planned End Date changed from 13 Oct 2024 to 13 Oct 2025.
15 Feb 2023 Planned primary completion date changed from 13 Oct 2023 to 13 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight